These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37294247)

  • 1. Mini-review: Equipment evaluation for process scalability and readiness for current Good Manufacturing Practices in cell therapy workflows.
    Verbarendse M; Snyder R; Lakshmipathy U
    Cytotherapy; 2023 Oct; 25(10):1107-1112. PubMed ID: 37294247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biopharmaceutical Industry Approaches to Facility Segregation for Viral Safety: An Effort from the Consortium on Adventitious Agent Contamination in Biomanufacturing.
    Barone PW; Avgerinos S; Ballard R; Brussel A; Clark P; Dowd C; Gerentes L; Hart I; Keumurian FJ; Kindermann J; Leung JC; Ly N; Mink S; Minning S; Mullberg J; Murphy M; Nöske K; Parriott S; Shum B; Wiebe ME; Springs SL
    PDA J Pharm Sci Technol; 2019; 73(2):191-203. PubMed ID: 30361281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interfacing data science with cell therapy manufacturing: where we are and where we need to be.
    Wang B; Chen RQ; Li J; Roy K
    Cytotherapy; 2024 Sep; 26(9):967-979. PubMed ID: 38842968
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equipment and analytical companies meeting continuous challenges. May 20-21, 2014 Continuous Manufacturing Symposium.
    Page T; Dubina H; Fillipi G; Guidat R; Patnaik S; Poechlauer P; Shering P; Guinn M; Mcdonnell P; Johnston C
    J Pharm Sci; 2015 Mar; 104(3):821-31. PubMed ID: 25448273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Towards a common framework for defining ancillary material quality across the development spectrum.
    Ball O; Zylberberg C
    Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
    Abbasalizadeh S; Baharvand H
    Biotechnol Adv; 2013 Dec; 31(8):1600-23. PubMed ID: 23962714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of contracted manufacturing organization protocols on operations in an aca demically based Current Good Manufacturing Practice facility.
    Sutherland V; Buffo MJ; Whiteside TL
    Cytotherapy; 2022 Jan; 24(1):32-36. PubMed ID: 33610480
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Raising the standard: changes to the Australian Code of Good Manufacturing Practice (cGMP) for human blood and blood components, human tissues and human cellular therapy products.
    Wright C; Velickovic Z; Brown R; Larsen S; Macpherson JL; Gibson J; Rasko JE
    Pathology; 2014 Apr; 46(3):177-83. PubMed ID: 24614714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. What does cell therapy manufacturing cost? A framework and methodology to facilitate academic and other small-scale cell therapy manufacturing costings.
    Ten Ham RMT; Hövels AM; Hoekman J; Frederix GWJ; Leufkens HGM; Klungel OH; Jedema I; Veld SAJ; Nikolic T; Van Pel M; Zwaginga JJ; Lin F; de Goede AL; Schreibelt G; Budde S; de Vries IJM; Wilkie GM; Dolstra H; Ovelgönne H; Meij P; Mountford JC; Turner ML; Hoefnagel MHN
    Cytotherapy; 2020 Jul; 22(7):388-397. PubMed ID: 32414635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance.
    Nath SC; Harper L; Rancourt DE
    Front Bioeng Biotechnol; 2020; 8():599674. PubMed ID: 33324625
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Status of PRP Manufacturing Requirements & European Regulatory Frameworks: Practical Tools for the Appropriate Implementation of PRP Therapies in Musculoskeletal Regenerative Medicine.
    Sebbagh P; Cannone A; Gremion G; Gremeaux V; Raffoul W; Hirt-Burri N; Michetti M; Abdel-Sayed P; Laurent A; Wardé N; Applegate LA
    Bioengineering (Basel); 2023 Feb; 10(3):. PubMed ID: 36978683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality Risk Management: Putting GMP Controls First.
    O'Donnell K; Greene A; Zwitkovits M; Calnan N
    PDA J Pharm Sci Technol; 2012; 66(3):243-61. PubMed ID: 22634590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Developments and opportunities in continuous biopharmaceutical manufacturing.
    Khanal O; Lenhoff AM
    MAbs; 2021; 13(1):1903664. PubMed ID: 33843449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Research and Development of Manufacturing of Biologics-the Activities of Manufacturing Association of Biologics].
    Omasa T
    Yakugaku Zasshi; 2022; 142(7):723-729. PubMed ID: 35781501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of manufacturing practices on quality of pharmaceutical products manufactured in Kenya.
    Orwa JA; Keter LK; Ouko SP; Kibwage IO; Rukunga GM
    East Afr Med J; 2004 Jun; 81(6):287-92. PubMed ID: 16167675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First update of the International Xenotransplantation Association consensus statement on conditions for undertaking clinical trials of porcine islet products in type 1 diabetes--Chapter 3: Porcine islet product manufacturing and release testing criteria.
    Rayat GR; Gazda LS; Hawthorne WJ; Hering BJ; Hosking P; Matsumoto S; Rajotte RV
    Xenotransplantation; 2016; 23(1):38-45. PubMed ID: 26923763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The implementation of tissue banking experiences for setting up a cGMP cell manufacturing facility.
    Arjmand B; Emami-Razavi SH; Larijani B; Norouzi-Javidan A; Aghayan HR
    Cell Tissue Bank; 2012 Dec; 13(4):587-96. PubMed ID: 21870140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multivariate data analysis in cell gene therapy manufacturing.
    Emerson J; Kara B; Glassey J
    Biotechnol Adv; 2020 Dec; 45():107637. PubMed ID: 32980438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Manufacturing readiness assessment for evaluation of the microneedle array patch industry: an exploration of barriers to full-scale manufacturing.
    Creelman B; Frivold C; Jessup S; Saxon G; Jarrahian C
    Drug Deliv Transl Res; 2022 Feb; 12(2):368-375. PubMed ID: 34655041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.